EA2165-A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer

January 06, 2020
https://clinicaltrials.gov/ct2/show/NCT03233711
Cancer - Colorectal
Principal Investigator: Ding Wang, MD
High risk anal cancer, anal cancer, invasive squamous cell carcinoma of the anus, rectal cancer
Open
313-916-3731